KWM
RNTX

Keebeck Wealth Management’s Rein Therapeutics RNTX Stock Holding History

Keebeck Wealth Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,350
Closed -$14K – 260
2022
Q1 		$14K Sell
1,350
-2,150
-61% -$19.5K ﹤0.01% 233
2021
Q4 		$39K Sell
3,500
-300
-8% -$4.64K 0.01% 214
2021
Q3 		$78K Sell
3,800
-3,981
-51% -$87.2K 0.02% 207
2021
Q2 		$195K Sell
7,781
-355
-4% -$8.86K 0.03% 234
2021
Q1 		$233K Buy
+8,136
New +$279K 0.04% 216

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Keebeck Wealth Management's RNTX Position: Q2 2022 in Review

Keebeck Wealth Management sold out of Rein Therapeutics (RNTX) in Q2 2022, closing a stake of 1,350 shares — an estimated $14K sold.

Keebeck Wealth Management first reported a position in RNTX in Q1 2021 and held it in 5 quarters. The position peaked at $233K in Q1 2021. 37 funds tracked by Wall St. Rank hold RNTX as of Q2 2022.

  • Keebeck Wealth Management reported no remaining Rein Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Keebeck Wealth Management sold 1,350 Rein Therapeutics shares in Q2 2022, an estimated $14K.
  • Keebeck Wealth Management first reported a position in Rein Therapeutics in Q1 2021 and held it in 5 quarters.
  • Keebeck Wealth Management's Rein Therapeutics position peaked at $233K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2022.

Based on Keebeck Wealth Management's 13F filing for Q2 2022, filed 15 Aug 2022.